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制。因此开发新型高效低毒的抗肿瘤光敏剂一直是 PDT 研究的热点。 











DVDMS-2 浓度，采用 Winnonlin 药代动力学软件包拟合。 后，CellTiter-Blue® 
Cell Viability Assay 法检测 DVDMS-2 对肿瘤细胞的光动力杀伤活性；用小鼠 H22
皮下肿瘤模型检测 DVDMS-2-PDT 的抗肿瘤活性；共聚焦荧光显微镜观察肿瘤
细胞对 DVDMS-2 的摄取随时间变化关系；AnnexinⅤ/PI 双染结合荧光显微镜和
流式细胞仪观察检测 DVDMS-2-PDT 对肿瘤细胞杀伤模式。  

























度保持峰值的 80%，肿瘤与其周边皮肤和肌肉的药物分布比分别为 7:1 和 5:1。
（4）DVDMS-2 对不同肿瘤细胞株均有显著的杀伤作用（IC50 在 0.20~0.83μg/mL
范围内），杀伤作用在一定范围内与光敏剂浓度和光照剂量呈正相关；
DVDMS-2-PDT 14 天后小鼠肿瘤消失，DVDMS-2-PDT 对荷 H22 瘤小鼠的抗肿
瘤作用显著；在 DVDMS-2 孵育 5h 细胞对药物的摄取达到峰值；AnnexinV/PI 双
染分析结果显示，低 PDT 剂量主要诱导肿瘤细胞凋亡，细胞凋亡率可达 19.47%，





且 DVDMS-2 能选择性聚集并较长时间潴留于肿瘤组织，光动力治疗的 佳时间
为静脉注射后 12h 至 24h。（4）DVDMS-2-PDT 对体内外肿瘤均表现出显著的抗
肿瘤活性，体外杀伤作用呈药物和光剂量依赖性；体外 PDT 佳实验参数：
1μg/mL DVDMS-2，避光孵育 5h，光剂量 10J/cm2；（5）DVDMS-2-PDT 对肿瘤
细胞的杀伤是通过诱导细胞凋亡和坏死双重模式进行。 
















Background and Objectives: Photodynamic therapy (PDT) is a newly 
developed therapeutic method for malignant tumors during the past 30 years. 
Compared to the three traditional cancer treatment methods (surgery, chemotherapy 
and radiotherapy), PDT has several characteristcs including relative high selectivity, 
directional tumor eradication, less normal tissue damage, less toxic side effects; being 
concomitant with chemotherapy and radiotherapy; curative effects on various solid 
tumors and availability in repeatable treatments, etc.. Photosensitizer is the most key 
factors involved in PDT, but there are many fatal weakness in early photosensitizers 
such as PHOTOFRIN®. The main disadvantages of PHOTOFRIN® include low 
uptake rate in tumor cells, complex composition, instability of the composition, 
difficult sources and so on. All these lead to instable therapeutic efficacy and 
restricted clinical application. Therefore, the development of new high-efficiency and 
low-toxicity photosensitizers has been the hot topic of PDT. 
DVDMS is ether bond-linked porphyrin dimer salts, with DVDMS-2 as the main 
component. DVDMS-2 is a new photosensitizer which is clear in chemical structures, 
soluble in water, and stable in other properties. This paper aims to study the spectrum 
characteristics of DVDMS-2, to establish a rapid and sensitive method for the 
quantitation of DVDMS-2 in biological samples by Fluorescence spectrometer, to 
study the pharmacokinetics of DVDMS-2 in mice bearing hepatoma-22 (H-22) solid 
tumors, to test the DVDMS-2-PDT anti-tumor activity in vivo and in vitro, and to 
investigate the cytotoxic mechanism of DVDMS-2-PDT in cancer cell lines.  
Methods: Firstly, the UV-vis absorption spectroscopy and fluorescence 
spectroscopy of DVDMS-2 in different solution systems were studied using 
UVmini-1240 UV-vis Spectrophotometer and LS-55 Fluorescence Spectrometer. 















from mice tissue, then the Fluorescence assay for the quantitation of DVDMS-2 in 
biological samples was established. Validation of the fluorescence assay for 
DVDMS-2 determination with the specificity, precision, accuracy, recovery, detection 
limits of the method were studied. Secondly, a H22 subcutaneous tumor model was 
established in Kunming mice. After tail vein injection of DVDMS-2 with three 
dosages (1, 2, and 4mg/kg), the DVDMS-2 in biological samples were determined by 
the fluorescence assay. The data obtained were processed with Winnonlin 
pharmacokinetic procedure. Finally, the cytotoxicity of DVDMS-2-PDT was 
measured by CellTiter-Blue® Cell Viability Assay; and the anti-tumor activity of 
DVDMS-2-PDT on H22 hepatoma-bearing mice was evaluated too. Cells were 
subjected to Confocal microscopy at different indicated times using a 20x objective to 
detect cellular uptake of DVDMS-2. AnnexinⅤ/ PI double staining of cells were 
analyzed with fluorescence microscopy and flow cytometry to detect the modes of 
DVDMS-2-PDT on tumor cell destruction. 
Results: (1) UV-vis spectral characteristics of DVDMS-2 in PBS: there are four 
absorption peaks (223, 374, 526, 588 nm) in the range of 200~700nm, λmax=374nm, 
and lower limit of quantification was 4μg/mL and merely influenced by serum. 
Fluorescence spectral characteristics of DVDMS-2 in PBS: Ex=408nm, 
Em=628~631nm. Fluorescence intensity was significantly enhanced with the addition 
of serum and the lower limit of quantification was 10ng/mL. (2) A new fluorescence 
assay for DVDMS-2 determination had been established. Its detection conditions are 
as followed: PBS:methanol (v/v 1:2) as extracting solvent, DVDMS-2 in biological 
samples detected by LS-55 fluorescence spectrometer with Ex=408 nm and 
Em=628~631nm. All the correlation coefficients (r) in various tissues are larger than 
0.996, and the lower limit of quantification was 20ng/mL. (3) The pharmacokinetics 
of DVDMS-2 in tumor-bearing mice was conformed to a two-compartment model 
with T½α of 0.12h, 0.13h, 0.42h; T½β of 7.68h, 5.07h, 6.94h at the dose of 1, 2 and 















tissues with a single-dose (2mg/kg) after intravenous injection. 24h after the 
DVDMS-2 administration, the elimination in tissues were mostly completed, while 
the drug contcentration in tumor still hold above 80% of the peak. The 
tumor-to-normal tissue ratios were 5:1 and 7:1 in skin and muscle, respectively.(4) 
Our study showed that 14 d after PDT same tumor disappeared, showed significant 
anti-tumor activity of DVDMS-2-PDT on H22 hepatoma-bearing mice,DVDMS-2 
also showed a significant killing-effect on different tumor cell lines with the IC50 at 
the range of 0.20~0.83μg/mL. And the anti-tumor activity of DVDMS-2 in vivo was 
dose-dependent and light-dependent. The peak fluorescence intensity of DVDMS-2 in 
BEL-7402 cells appeared at the 5th of incubation. Fluorescence microscopy and flow 
cytometry analysis in Annexin-V/PI double staining showed that DVDMS-2-PDT at 
low dose of DVDMS-2 mainly induced tumor cell apoptosis with an apoptosis rate of 
19.47% and a necrosis rate of 5.98%. DVDMS-2-PDT at high dose of DVDMS-2 
mainly induced tumor cell necrosis with a necrosis rate of 85.74% and an apoptosis 
rate of 3.78%. 
Conclusion: (1)The UV and fluorescence spectral characteristics of DVDMS-2 
are basically the same as other porphyrin photosensitizer.(2) DVDMS-2  fluorescent 
quantitative assay we established is a sensitive, rapid, reproducible method for the 
determine of DVDMS-2 in biological samples. (3) The pharmacokinetics of 
DVDMS-2 in tumor-bearing mice is conformed to a two compartment model. There 
is a higher retention of DVDMS-2 in tumors tissue compared with surrounding 
normal tissues. The best time window for DVDMS-2-PDT is 12~24 h after 
administration.(4) DVDMS-2 had a significant anti-tumor activity in vivo and in vitro. 
The anti-tumor activity of DVDMS-2 was dose-dependent and light-dependent. The 
best experimental parameters in vitro: 1μg/mL DVDMS-2, dark incubated for 5hs, 
light dose of 10J/cm2. (5) DVDMS-2-PDT cytotoxicity on tumor cells may be through 
induction of both apoptosis and necrosis modes. 
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年新增癌症病例 1200 万人，并有 760 万人死于癌症。我国 2002 年的 新统计资
料显示，我国有癌症患者 300 多万，且以每年 3%的增长速度递增。世界卫生组
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